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Abstract
In the last decades, there has been a remarkable advance in the treatment of 
most types of cancer, improving the patient’s prognosis. During cancer progression, 
tumor cells develop several biological changes to support initiation, proliferation, 
and resistance to death. Nearly 50–80% of all oncologic patients experience rapid 
weight loss that is related to ~20% of cancer-related deaths. Cancer cachexia is a 
syndrome characterized by loss of skeletal muscle mass, anorexia, and anemia. 
A lot of effort in scientific investigation has contributed to the understanding of 
cancer processes, in which epigenetic changes, as microRNAs, can influence cancer 
progression. Therefore, useful strategies to control the cancer-induced epigenetic 
changes in the tumor cells can have a key role in a clinical perspective to decrease 
the cancer development and aggressiveness. Physical activity has been proposed 
as a suitable tool to manage tumor growth and cachexia and to improve the del-
eterious sequelae experienced during cancer treatment. Although the molecular 
mechanisms involved in these responses are poorly understood, this chapter aims 
to discuss the role of microRNAs in the cancer-induced epigenetic changes and how 
physical activity could influence the epigenetic control of tumor cells and cachexia 
and their potential role in clinical applications for cancer.
Keywords: epigenetic, cancer, hallmarks of cancer, cachexia, physical activity,  
tumor progression, microRNAs
1. Introduction: hallmarks of cancer, genetics and epigenetics
In the last decades, there has been a remarkable advance in the treatment of most 
types of cancer, improving the patient’s prognosis [1]. However, cancer remains 
the second major cause of death in the world and major cause of death in the rich 
countries [2, 3]. Cancer consists in a set of diseases characterized by the progres-
sive accumulation of mutations in the cell. These mutations provide changes in 
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the intracellular environment that induce advantages for its proliferation as well as 
greater resistance to mechanisms of cell death. A dysfunctional cluster of these cells 
is classically known as tumor. Currently, cancer is understood as a microenviron-
ment, in which the interactions between the cellular elements that compose it are 
determinants for the progression of the disease. For example, such elements would 
be involved in the interaction of tumor cells with normal cells such as fibroblasts, 
adipocytes, immune system cells, and endothelial cells [4–6]. All these cellular 
interactions support the development of cancer cachexia, which affects approxi-
mately 50–80% of cancer patients, and more than 25% of cancer deaths are a direct 
consequence of cachexia [7]. Cancer cachexia is directly related to a reduction in 
tolerance to physical effort [8], a reduction in tolerance to cancer treatments [9], 
and a shorter patient survival [10].
During cancer progression, tumor cells develop a number of important biologi-
cal changes to support initiation, proliferation, and resistance to death known 
as cancer hallmarks [5, 6]. Hanahan and Weinberg [5, 6] discuss 10 biological 
capabilities acquired by tumor cells that may be common among the different 
neoplasms and are important for the development and growth of the tumor mass, 
namely: (1) sustaining proliferative signaling, (2) loss of growth suppressors, (3) 
resisting cell death, (4) enabling replicative immortality, (5) inducing angiogenesis, 
(6) activating invasion and metastasis, (7) genome instability, (8) inflammation, 
(9) reprogramming of energy metabolism, and (10) loss of immune destruction 
[5, 6]. Among the 10 cancer-related biological processes, we point out that 6 are of 
fundamental importance for tumor mass growth.
1. Sustaining proliferative signaling
In normal tissues, there is a careful control of the release of growth and 
proliferation factors for the regulation of the cell cycle, which ensures adequate 
tissue architecture and function. However, tumor cells show abnormal prolif-
eration signaling, which promote exacerbated cell proliferation that generates 
morphological and functional tissue disarrangement. Some mutations are 
shown as probable causes of a normal cell to initiate a sustained prolifera-
tion and tumorigenesis. For example, mutation of PIK3CA gene and tyrosine 
kinases are mutations well described that promote sustained proliferation of a 
tumor cell [11].
2. Loss of growth suppressors.
Tumor cells bypass growth suppressor signals through the escape of mecha-
nisms that negatively control cell proliferation. Usually, tumor cells show loss 
of p53, a well-known tumor suppressor that controls proliferation, senescence, 
and cellular apoptotic programs, culminating in the uncontrolled growth of 
tumor cells. Tumor cells must also bypass powerful programs that negatively 
regulate cell proliferation; many of these programs depend on the actions of 
tumor suppressor genes [12].
3. Resisting cell death.
Over the past few decades, the literature has shown that apoptosis-
programmed cell death serves as a natural barrier to the development of 
cancer. Apoptosis is triggered in response to various physiological stresses 
that tumor cells undergo during the course of tumorigenesis or as a result 
of antineoplastic therapies. However, tumor cells have the ability to resist 
apoptosis and subsequently progress to conditions of malignancy and 
resistance to therapy [5].
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4. Enabling replicative immortality.
In healthy tissues, most normal cells have growth and cell division capacity 
controlled, but tumor cells have unlimited replicative potential, which favors 
the development of tumors [5].
5. Inducing angiogenesis.
In any tissue, the presence of vessels allows both the uptake of nutrients and 
oxygen and the release of substances not useful for the cells. Moreover, angio-
genesis occurs temporarily in response to some stimulation such as healing and 
the female reproductive cycle, being a transient process. However, this process 
is sustained and dysfunctional, since new vessels that present less coverage of 
pericytes appear continuously, favoring tumor growth [5].
6. Activating invasion and metastasis.
Tissue invasion and metastasis are probably the most relevant features 
developed by tumor cells, since the major cause of cancer death is associated 
with the formation of metastatic tumors. Metastasis is the formation of a new 
tumor, originating from the primary tumor. This is a complex process in which 
primary tumor cells invade blood and lymphatic circulation, spreading and 
forming colonies at distant sites from the primary tumor [13].
To reach the circulation and invade distant tissues, tumor cells need to modify 
their configuration and undergo a process named epithelial-mesenchymal transition 
(EMT). Thus, tumor cells with epithelial characteristics deactivate the mechanisms of 
cell adhesion and acquire locomotor properties, becoming able to infiltrate the stroma 
and have access to blood and lymphatic vessels [14, 15]. Moreover, for the colonization 
of tumor cells in distant tissues, the preparation of the “premetastatic niche,” which 
corresponds to the preparation of the metastatic tissue target of the tumor cells, is 
fundamental. The process of formation of the premetastatic niche involves an intricate 
cellular signaling at the systemic and local level, involving tumor-secreted factors and 
tumor-shed extracellular vesicle interaction [16]. Additionally, although Hanahan 
and Weinberg [5, 6] demonstrate possible treatments against hallmarks of cancer, the 
individual response to various treatments is still unpredictable [17, 18], demonstrat-
ing the plasticity of tumor cells [19–23]. The understanding of premetastatic niche is a 
new paradigm for the initiation of metastasis that can enable the clinical body to fight 
metastasis, and would benefit greatly from understanding the pathological processes 
occurring before the development of macrometastases [24].
2. Epigenetics and cancer
Cancer is considered a typically genetic disease; however, epigenetic modifications 
play an important role in the development and progression of cancer [5, 6, 25–27].
The term “epigenetics” was originally described by Conrad Waddington to 
describe hereditary changes in a cell phenotype that were independent of changes in 
DNA sequence [28].
Epigenetic modifications reflect a complexity of factors that determine the 
condensation state of chromatin, which determines whether the DNA is accessible to 
proteins that control gene transcription. A relaxed or “open” chromatin state allows 
gene transcription, while a condensed or “closed” chromatin condition prevents gene 
transcription [25, 26, 28–31]. Epigenetic mechanisms currently believed to play a 
role in the development of cancer include: (1) DNA methylation of cytosine bases 
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in CG-rich sequences, called CpG islands; (2) posttranslational modification of his-
tones (proteins that form the nucleosomes), which regulate the packaging structure 
of DNA (called chromatin); and (3) microRNAs (miRs) and noncoding RNAs [25, 
26, 28–31].
Although DNA methylation and histone modifications are important com-
ponents of epigenetic regulation [25, 26, 28–31], here we will focus on the role of 
alterations in miRs expression, since their expression is regulated through various 
mechanisms, including epigenetic modifications, and because their functions are 
aberrant in cancer, boosting the progression of the disease.
3. MicroRNAs
MiRs are a class of molecules that have an important role in the regulation of 
protein expression, even after the transcription of messenger RNA (mRNA).
MiRs are characterized as small RNAs of approximately 17–22 nucleotides, 
noncoding proteins, that act by binding to the mRNA, repressing the translation of 
proteins. MiRs are found in several organisms as animals and plants and control a 
lot of physiological and pathological processes. Evidence shows that at least one-
third of all biological processes are controlled by miRs [32].
This class of molecules was first observed in 1993 by Lee et al., which demon-
strated that miR lin-4 was associated with larval development of C elegans [33]. 
Although the discovery of the first miR occurred in 1993, miRs researches only pro-
gressed in the year 2000, when miR lin-4 was found to participate in the posttran-
scriptional control of lin-14 protein through the complementary binding of miR 
with the 3’ untranslated region (3’UTR region) of the protein mRNA [34]. After the 
pioneering study by Hong et al., many studies have been developed to demonstrate 
that small RNAs could participate in posttranscriptional controls. Thus, Ambros 
observed that miR let-7 had a partially complementary binding to the 3’UTR region 
of the lin-4 protein mRNA, negatively controlling its protein expression [34, 35]. 
These findings led to the discovery of new miRs, and more than 30,000 mature 
miRs are now known in the most diverse organisms [32].
As mentioned, miRs exert their action through partially or totally binding to 
the 3’UTR region of the target mRNA. The complete complementarity induces 
the degradation of the mRNAs, being commonly observed in plants. In mam-
mals, there is partial complementarity, which inhibits the translation of the target 
transcript [36].
The miRs bind their seed region, that in mammals comprises 2–8 nucleotide, 
with the target mRNA, present in the 3’UTR region, where only some of the base 
pairs are complementary. Due to the imperfect pairing and small size of these 
molecules, there is the possibility of an miR presenting various targets [36].
The biogenesis of miRs begins with the action of the enzyme RNA polymerase 
II that generates a primary transcript called pri-miR. The pri-miR has a hairpin 
double helix structure with approximately 300 nucleotides. Still in the cell nucleus, 
the Drosha enzyme and its cofactor DGCR8 cleave the pri-miR, forming its 
precursor, the pre-miR. The pre-miR is exported to the cytosol by the exportin 5 
enzyme. In the cytoplasm, the pre-miR is cleaved by the enzyme dicer, originating 
two strands together, one being the mature miR and the other called an antisense. 
Dicer cleaves again and separates the duplex. The mature miR is then incorporated 
by a multimeric complex named RISC that contains argonaute protein (AGO) as 
showed in Figure 1, while the other strand can be degraded or incorporated in 
other RISC complex to exert negative regulation of target mRNAs [32].
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Recently, the interest in the study of miRs has increased, since they exert a 
paracrine function and are effective in the tissue communication. Also, an miR can 
exert the same function on different cell types, as different function in the same 
cells. In 2008, the presence of miRs in plasma and other biological fluids was dis-
covered, demonstrating that miRs are viable in the extracellular environment and 
important signaling molecules. There are circulating miRs in almost all biological 
fluids, including: milk, plasma, serum, saliva, urine, tear, and amniotic fluid [37]. 
Circulating miRs are remarkably stable, resis tant to RNase activity, freeze-thaw 
cycles as well as extreme pH. This stability is associated with the carriers that carry 
them and can be secreted by the cells through different vesicles such as exosomes, 
HDL, or AGO proteins containing apoptotic bodies [37].
Figure 1. 
Canonical pathway of biogenesis of miRs [31]. https://smart.servier.com/image-set-download/.
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4. microRNAs and cancer
The miRs play a key role in the control of various physiological and pathological 
processes. Many studies demonstrate the participation of miRs during the progres-
sion of several types of cancer. MiRs present altered expression in tumors, and 
many studies are being conducted with this new class of molecules to elucidate their 
role in controlling the pathophysiology of the disease [36, 38, 39].
There is evidence that miRs are also involved in regulation of hallmarks of cancer 
and thus in the progression of cancer [5, 15]. In view of this, there is an effort by the 
scientific community to understand the mechanisms involving miRs and the devel-
opment of cancer aiming to develop cancer-specific gene therapies [40]. The aim of 
these efforts is to improve responses to conventional drugs for the cancer treatment, 
specifically suppress oncogenic processes, and improve the prognosis of the disease.
The miR-124 was one of the first studied miRs involved in the pathogenesis 
of cancer [41]. MiR-124 was silenced in more than 10 types of cancer, as breast, 
colorectal, liver, and lung cancer. This silencing promotes increased expression 
of CDK6, which affects the phosphorylation state of Rb protein, favoring tumor 
progression [42]. Other miRs silenced are miR-9-1 and miR-9-3. When analyzing 
the expression of miR-9-3 in primary and metastatic tumors, it was observed that 
metastatic tumors have a lower expression of miR-9-3. Also, patients with lower 
miR-9-3 expression in the tumor have a lower survival rate than patients with 
higher expression of miR-9-3 [43].
Garzon et al. [40] observed that there is a decrease in miRs-15a/16 expression 
in patients with chronic lymphoid leukemia and in chronic lymphocytic leukemia 
tumor cells CLL23. Thus, the authors ectopically increased the expression of 
miRs-15a/16 in CLL23 tumor cells and investigated the processes of proliferation 
and apoptosis. It was observed that with the increase of miRs-15a/16 expression in 
CLL23 tumor cells, there is a higher apoptosis and less cellular proliferation. This 
response occurs because miRs-15a/16 target BCL-2 protein, an important antiapop-
totic factor. BCL-2 is known to be increased in tumors of cancer patients [40].
Moreover, miR-34 has been shown to be downregulated in pancreatic cancer. 
The overexpression of miR-34 in these cells increases apoptosis and inhibition of 
autophagy, reducing tumor growth [44]. Another example is the miR Let-7 family, 
which targets HRAS and HMGA2 as well as participates in the regulation of prolif-
eration and cell cycle. Let-7 family members are also negatively regulated in various 
types of cancers, and their overexpression results in inhibition of tumor growth in 
different cancer models [45, 46]. This is due to the fact that Let-7 targets the major 
components of cell cycle progression, such as KRAS, CCDN1, CDC34, HMGA2, 
E2F2, and Lin28 [45, 46].
In contrast, miRs may also be increased in cancer and their biological effects 
may potentiate the development of the disease. For example, the case of miR-21 has 
a high expression in tumors of glioblastoma, pancreatic cancer, breast cancer, and 
colon cancer. Inhibition of miR-21 in glioblastoma cells was able to increase caspase 
activity and promote apoptosis of tumor cells. One possible explanation is that 
miR-21 targets PTEN protein and PDCD4 protein, functioning as an antiapoptotic 
agent in cancer [47].
MiRs are also involved in several other cancer factors, such as in the formation of 
metastases. Zhou et al. [48] observed that miR-105 is involved with preparation of 
the “premetastatic niche.” The authors demonstrated that animals with breast cancer 
exhibit high levels of miR-105 expression in both tumor and circulation and that ele-
vated miR-105 levels in the circulation promote the destruction of endothelial barriers 
and increase vascular permeability in the target metastatic organ. Inhibition of miR-
105 in tumor cells from highly metastatic breast cancer prevented the development of 
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metastasis [48]. Another miR associated with metastasis formation is the family of 
miR-200. The 200 family plays a role in repress proteins that promote the epithelial-
mesenchymal transition. However, its expression is reduced in tumors in response 
to increased expression of the long noncoding RNA ATB that competes with the miRs 
binding site of the 200 family, reducing its expression and function, which favors the 
negative regulation of E-cadherin and increase of ZEB proteins expression [49]. The 
current involvement of miRs in the hallmarks of cancer is elucidated in Figure 2.
4.1 Physical activity as nonpharmacological therapy
Although in recent time cancer treatments have evolved considerably, there are 
still no responsive patients to the treatments, which suggest the need for strategies 
to reduce the incidence and aggressiveness of cancer. At same time, American Cancer 
Society recommends to cancer survivors the participation in 150 min of moderate 
intensity exercise per week. There is evidence that physical activity improves quality 
of life, treatment response, decreases cancer recurrence due physical fitness improve-
ment of patients, and survivors [50]. In the present moment, there is strong academic 
effort in clinical trials being performed, investigating about perspective and limita-
tion of inclusion physical activities in the cancer therapy. The main investigations 
focus in physiological aspects and appropriate modalities and methods [51–53].
Figure 2. 
Landscape of investigative field involving miRs, molecular basis, and the hallmarks of cancer. Currently, 
among the miRs related to the cancer hallmarks, only miR-21 and its target, the mRNA of PDCD4, PTEN, 
TPM1, HIF1α and VEGF was established the beneficial relationship with the effects of physical activity in the 
tumor (thin green arrows) [43–49, 83, 84]. https://smart.servier.com/image-set-download/.
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Physical fitness is the ability to perform daily tasks with vigor and alertness, 
without excessive fatigue and with energy to enjoy leisure activities and to meet 
unforeseen emergencies [54]. It is known that physical activity induces beneficial 
adaptations to the body, improving physical fitness [55]. Physical activity encom-
passes both physical exercise with controlled volume, intensity, and duration 
or recreational activities [56]. There is evidence that support the importance of 
maintaining a physically active life for health. Healthy individuals or cardiovascular 
patients who have low physical capacity tend to have a lower survival rate [57]. 
Corroborating with these clinical and epidemiological data, experimental results 
show that rats with high capacity to run present a higher survival (~45%) when 
compared to those that have low capacity to run [58, 59]. Regular physical activities 
are recognized as nonpharmacologic preventive approach and treatment for chronic 
diseases [60–62], including cancer [63–65]. Several studies also demonstrate 
that aerobic physical activity normalizes the expression of aberrant miRs due to 
diseases such as myocardial infarction, hypertension, diabetes, and obesity. That 
these pathologies induce molecular and structural alterations and aerobic physical 
exercise is a beneficial stimulus for the reversal and control of these deleterious 
alterations such as muscle mass decrease and microvascular rarefaction [66–69].
4.2 Physical activity, cancer, and microRNAs: new perspectives
There is evidence that aerobic physical activity reduces the incidence of several 
types of cancer [65]. Moore et al. [65] demonstrated that regular physical activity 
resulted in decreased incidence of 13 types of cancer in 26 analyzed in 1.44 mil-
lion adults. The individuals involved with higher daily volumes of physical activ-
ity presented decrease in the incidence in esophageal adenocarcinoma, myeloid 
leukemia, myeloma, liver, lung, kidney, gastric, endometrial, colon, head and neck, 
rectal, bladder, and breast cancer. The effects of physical activity on reducing the 
incidence of cancer were independent of other factors such as body mass index 
(BMI), smoking, geographical region, use of hormonal therapy, and ethnicity [65]. 
Cancer patients with reduced physical capacity have a worse prognosis [70–72]. 
Colon cancer patients have a reduction of more than 20% in maximal oxygen 
consumption (VO2 máx.) compared to their healthy peers [71]. Patients with lung 
cancer and colon cancer with greater physical capacity present a higher survival 
compared to patients with lower physical capacity [73]. Aerobic physical activity 
attenuates tumor growth in different animal models [74–78]. However, the molecu-
lar mechanisms involved in this response are poorly understood. Recently, Pedersen 
et al. [79] showed that 4 weeks of prior voluntary physical activity was able to delay 
tumor initiation and attenuate tumor growth in various cancer models in mice and 
was also efficient in decreasing the formation of metastatic nodules. The authors 
demonstrated that physical activity increases the mobilization and redistribution 
of NK cells to the tumor microenvironment due to the systemic increase of IL-6 
and epinephrine induced by physical activity. This increase of immune response 
in the tumor microenvironment was proposed as the main mechanism induced by 
aerobic physical activity for the attenuation of tumor growth [79]. Betof et al. [77] 
also demonstrated that previous aerobic physical activity is capable of attenuat-
ing tumor growth in the 4T1 breast cancer model. The authors demonstrated that 
aerobic physical activity increased the pericytic coverage of tumor vessels and 
apoptosis of tumor cells, provided a greater functional neo-vascularization on the 
tumor endothelium, and consequently reduced the hypoxia regions in the tumor 
microenvironment [77]. Pigna et al. demonstrated that aerobic physical activity is 
also efficient in increasing the survival of animals injected with C26 (colon cancer) 
tumor cells lineages [80].
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However, it is important to note that only two of the studies that observed 
attenuation of tumor growth induced by aerobic physical activity investigated the 
role of miR in this response, both in mice breast cancer injected with MC4-L2. 
Khori et al. observed that aerobic physical activity was efficient in reducing miR-
21 gene expression in animal tumors, inhibiting proliferation and migration of 
tumor cells. In addition, the miR-21 downregulation was associated with increase 
of gene and protein PDCD4 expression and TPM1, two tumor suppressor genes 
[81]. Isanejad et al. [82] also demonstrated that aerobic physical activity reduces 
tumor growth and increased the gene expression levels of miRs-206 and let-7 in 
the mammary tumor. Moreover, exercise-increased expression of miR-206 and 
let-7 decreased in the levels of gene expression of HIF-1α, CD31, and VEGF in 
mice, suggesting an anti-angiogenic effect, which contributed to the decrease of 
tumor angiogenesis and growth [82]. Both Khori et al. and Isanejad et al. observed 
involvement of miRs in the aerobic physical activity response, which enhanced the 
effects of treatment with tamoxifen and letrozole, respectively, on tumor growth 
and molecular responses [81, 82].
These results indicate the potential of physical activity in modulating the decom-
pensated miRs in the tumor. Also, we can point to the potential of physical activity 
to an improved miRs profile in the tumor, and their direct role in the reduction of 
the tumor growth and aggressiveness. However, currently there is a gap in elucidat-
ing about the global molecular mechanisms by which physical activity induces the 
phenotypical improvement. Therefore, the interaction between cancer, miRs and 
the effect of physical activity in the several cancer types is a promisor field of inves-
tigation that certainly will develop a lot of knowledge about preventive, therapeutic, 
as well as the mechanisms by which physical activity acts is cancer.
5. Cancer cachexia
Cancer cachexia (CC) is a multifactorial syndrome characterized by continuous 
loss of muscle mass that can be conjugated or not by loss of fat mass. CC cannot be 
completely reversed by conventional nutritional support and leads to progressive 
functional disability [83]. The pathophysiology of CC is characterized by a negative 
protein balance, anorexia, and metabolic abnormalities [84]. CC individuals usually 
present with muscle weakness, asthenia and poor response to anticancer treatment, 
all of these processes contributes to patient mortality [85, 86].
Muscle atrophy in CC results from the imbalance in protein turnover due to 
exacerbated proteolytic activation, reduction of protein synthesis pathways, and 
reduced regenerative capacity in skeletal muscle [87, 88].
In this context, it is essential to understand the role of epigenetic factors in the 
loss of muscle mass in CC. There is massive evidence that epigenetic factors, for 
example histone acetylation, DNA methylation and miRs orchestrate processes such 
as muscle proliferation and differentiation, as well as skeletal muscle regenerative 
capacity [89–92]. To elucidate about the epigenetic factors that lead to the loss of 
muscle mass in CC also may contribute to the emergence of new therapies for the 
prevention and treatment of the syndrome.
In this section, we will approach about the role of miRs in the regulation of 
muscular trophism. Skeletal muscle presents a set of miRs that are enriched in 
this tissue and mediate mechanisms of proliferation, differentiation, and protein 
synthesis. These miRs are known as myomiRs [32]. The most studied myomiRs are 
the -133a/b, −206, and −1 miRs. These miRs are known to display target genes such 
as IGF-1R, known hypertrophic pathway promoters [32] and PAX3 and PAX7, genes 
that regulates proliferation of satellite cells [93]. In another view, there are many 
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studies showing the role of several other miRs orchestrating prohypertrophic and 
procatabolic genes in the skeletal muscle [32, 94].
Interesting advances have been made in studies about the of role skeletal muscle 
enriched miRs in CC. Lee et al. [95] conducted a study in order to investigate the 
profile of miRs expressed in skeletal muscle of cachectic mice. The researchers 
performed a sequencing of the anterior tibial muscle of LLC tumor-bearing mice, 
animal model of orthotopic lung cancer, and compared them to healthy mice. The 
miRs-147-3p, −299a-3p, 1933-3p, 511-3p, 3473d, 233-3p, 431-5p, 665-3p, and 205-3p 
were found to be differently expressed. Genetic ontology analyzes of these miRs 
indicate a relationship with cellular survival pathways, inflammatory response, cell 
cycle, cell development, and cell morphology through crosstalk of several path-
ways, with target genes such as FOXO3, HRAS, P38, MAPK, MYC, and EIF4E. We 
can note that HRAS and MYC are also related to hallmarks of cancer [95].
Narasimhan et al. [96] conducted another study evaluating the profile of miRs 
in muscle tissue of CC patients. In this study, human rectal abdominal muscle 
samples were collected during the tumor resection surgery of colon and pancreatic 
cancer patients. Sequencing analyzes demonstrated that eight miRs were differen-
tially expressed between cachectic individuals and controls. The miRs let-7d-3p, 
3184-3p, and −1296-5p were selected and these miRs were increased in cachectic 
patients relative to controls. The authors performed in-silico analyzes and pointed 
out that these miRs targets genes related to adipogenesis, myogenesis (SULF1 and 
DLK1), inflammation, and immune response (RPS6KA6) [96].
The loss of fat mass is not present in all cases of CC; however, the role in energy 
metabolism of adipose tissue in CC is important. Therefore, studies are being 
conducted to understand the function of miRs in maintaining of adipose tissue in 
cachetic state. Kulyté et al. [97] conducted a sequencing analyzes of miRs in adipose 
tissue of cachectic and noncachectic gastrointestinal cancer patients, the authors 
found difference in expression of nine miRs between cachectic and noncachectic 
patients. MiR-378 was selected due to an increased expression in the adipose 
tissue of cachectic patients compared to noncachectic patients. The inhibition and 
overexpression of miR-378 on human adipose-derived stem cells were performed; 
overexpression of miR-378 decreased expression of the HSL, PLIN1, and ATGL 
protein and consequently increased lipids catabolism and release of glycerol [97].
MiRs are also present in body fluids such as saliva, tear, and blood. In this sense, 
studies are being conducted with the purpose of understanding the role of circulat-
ing miRs in CC. Okugawa et al. [98] showed that the expression of circulating miR-
21 increases in the patients with cachectic colon cancer; however, the expression of 
miR-21 is not different in the skeletal muscle in compared to noncachectic patients 
[98]. The circulating miRs can be studied as biomarkers for some pathological 
processes. Studies in humans and animals have looked for miRs that are biomarkers 
in order to early diagnose CC [94]; however, it should be noted that many of these 
miRs are not widely accepted as biomarkers by the medical and scientific commu-
nity and some are not even validated in humans [96].
The role of miR-21 in CC was also investigated by He et al. [99], which showed 
that miR-21-enriched exosomes were found in the circulation of pancreatic and lung 
cancer patients. Myoblast cells cultures treated with these miR-21-enriched exo-
somes showed an interaction of the microvesicle with the muscle cells that induced 
cell death via TLR8 protein, an endosomal receptor that recognizes single-stranded 
RNA (ssRNA), and can recognize ssRNA viruses such as Influenza, Sendai, and 
Coxsackie B viruses. TLR8 is a protein binding to RNA and is able to recruit MYD88 
and leads to activation of the transcription factor NF-κB and an antiviral response. 
TLR8 agonists have undergone clinical trials as immune stimulants in combination 
therapy for some cancers [99].
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There are few studies showing a direct association of the action of miRs and 
their targets about processes involved in the progression or reversal of CC. The 
issue promises a great field for development of results that can be clinically relevant 
and useful in the future. Additionally, skeletal muscle is highly responsive to both 
physical activity and CC, and investigation of skeletal muscle-enriched miRs and 
the effect of physical activity and exercise in these miRs are promising to elucidate 
about CC. The next section will cover this topic.
5.1 Relationship between physical exercise and the mediators of cachexia
There is massive evidence that support the importance of maintaining aerobic 
fitness for health. Low aerobic fitness is an independent indicator of early death in 
individuals with cardiovascular and/or healthy individuals [57]. The physical train-
ing regulates the expression of miRs in a profile that enables endurance performance 
and physical fitness. Aerobic exercise prevents a number of chronic-degenerative 
diseases [60], including cancer [65]. Resistance training increases muscle mass and 
strength and contributes to increased functional capacity [87]. Therefore, aerobic 
and resistance training are presented as a therapeutic potential for CC patients and 
presents an interesting field of investigation to clarify clinically relevant process 
related to CC. However, due to clinical difficulties and poor safety conditions, there 
is a lack in human studies about the role of physical exercise in CC patients. In this 
context, the use of animal models in well-controlled studies has shown that physical 
training may be promising in the treatment of CC. Oh et al. demonstrated that the 
C26, orthotopic colon cancer cachectic mice, when submitted to resistance training 
and aerobic training protocols presented lower muscle mass loss [100]. Partial pres-
ervation of muscle mass due to physical training is associated with higher expression 
of proteins such as mTOR, IGF, and myogenin in the trained C26 mice when com-
pared to sedentary C26 mice [100]. Pigna et al. demonstrated that voluntary aerobic 
activity in C26 mice also improves the autophagy flow preventing skeletal muscle 
loss in association with autophagy regulatory drugs [80]. Baggish et al. showed for 
the first time that miRs-21, miR-146a, and -133a are candidates to be biomarkers of 
aerobic physical training in the circulation [101].
Skeletal muscle trophism is regulated by the action of some miRs, and exercise 
controls the expression of these miRs. As example, IGF-IR mRNA encodes IGF1 
receptor protein and is a target of miR-133. A study shows that IGF-IR overexpression 
results in increased PI3K-AKT-mTOR pathway that mediated muscle hypertrophy, 
in myocyte cell culture, and that knockdown of IGF-IR decreases the hypertrophic 
signal. MiR-133 decreases the expression of IGF-IR, and consequently decreases AKT 
and mTOR phosphorylation, regulating the development of skeletal muscle [102]. 
Furthermore, aerobic physical exercise decreases the expression of miR-133a [103].
In conclusion, many studies show that both aerobic and resistance physical exer-
cise control the expression of miRs that are dysregulated by diseases as hypertension, 
diabetes, and obesity [68, 69, 104, 105]. Physical exercise rebalances the expression of 
the miRs involved with those alterations reverses structural deleterious changes in the 
skeletal muscle and restores tissue or prevents deterioration [66]. However, there are 
no studies designing an miR profile from CC skeletal muscle and the prevention of 
muscle catabolism by physical exercise, which is interesting for future investigation.
6. Conclusions
The effects of physical activity as nonpharmacological adjuvant for cancer 
patients are effective to the disease and survivorship in cancer, since it improves 
Epigenetics
12
quality of life and decreases the recurrence of cancer. Currently, there are massive 
efforts to include exercise in the therapeutic approach to patients. Furthermore, 
studies show several benefits of aerobic physical activity in reducing the risk of 
incidence of cancer. Physical activity also reduces expenditures for public health 
agencies, both by decrease of cancer incidence and can attenuate the side effects or 
resistance related to anticancer treatment. However, little is known about the epi-
genetic, molecular, and cellular mechanisms involved in this response, both related 
to hallmarks of cancer, to cachexia process, and the comprehension about physical 
training effect in oncologic patients remains incipient.
Recently, the attentions of several areas of the scientific community have turned 
to miRs, epigenetic regulators in different cellular processes, as in tumorigenesis. To 
date, studies postulating the effects of aerobic physical activity on the modulation 
of decompensated miRNAs in the tumor and its potential as cancer gene therapy in 
cancer are rare. Thus, the identification of miRs modified by cancer of sedentary 
animals in comparison with trained animals can lead to the identification of miRs 
with therapeutic potential and elucidate about epigenetic mechanisms involved in 
physical activity therapy. However, it is necessary to better understand these mecha-
nisms both in cell culture and in animal models of cancer in order to transpose into 
translational medicine in a whole approach. In this sense, extensive basic research is 
needed to elucidate these mechanisms in order to establish relationships about the 
role of miRs, the 10 biological capacities, the hallmarks of cancer, and if how these 
processes can be reversed by physical activity. Another interesting issue to be inves-
tigated is about the involvement of the miRs regulated by the physical activity in the 
CC and how these miRs are related to the 10 capacities and the hallmarks of cancer. 
These approaches can extensively clarify about cancer mechanisms and improve 
future physical activity therapy.
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3’UTR region 3’ untranslated region
AKT AKT serine/threonine kinase
AGO argonaute protein
ATGL patatin-like phospholipase domain-containing protein 2
BCL2 B-cell lymphoma 2
BMI body mass index
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CD324 cadherin 1
CDC34 cell division cycle 34
CDK6 cell division protein kinase 6
DGCR8 DiGeorge syndrome critical region gene 8 microprocessor protein
DLK1 delta like non-canonical Notch ligand 1
DNA deoxyribonucleic acid
E2F2 E2F transcription factor 2
EIF4E eukaryotic translation initiation factor 4E
EMT epithelial-mesenchymal transition
ETS1 ETS proto-oncogene 1
FOXO3 forkhead box O3
HDL high-density lipoprotein
HiF1α hypoxia inducible factor 1 alpha
HMGA2 high-mobility group AT-hook 2
HRAS HRas proto-oncogene
HSL hormone-sensitive lipase
IGF insulin-like growth factor
IGF-1R insulin like growth factor 1 receptor
IL-6 interleukin 6
MAPK mitogen-activated protein kinase
VO2máx maximal oxygen consumption
mRNA messenger RNA
miR microRNA
mTOR mechanistic target of rapamycin kinase
MYC Myc proto-oncogene
MyD88 myeloid differentiation primary response
NK cells natural killer cells
P38 mitogen-activated protein kinase 14
PAX3 paired box 3
PAX7 paired box 7
PDCD4 programmed cell death protein 4
PTEN phosphatase and tensin homolog
PIK3CA phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit 
alpha
PI3K phosphatidylinositol-4,5-bisphosphate 3-kinase
PLIN1 perilipin 1
PDCD4 programmed cell death 4
RISC RNA induced silencer complex
RPS6KA6 ribosomal protein S6 kinase A6
SULF1 sulfatase 1
TLR8 toll like receptor 8
TPM1 tropomyosin 1
VEGF vascular endothelial growth factor
ZO1 tight junction protein 1
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